VPT:CC - The Medical University of Vienna's Paediatric Heart Centre Purchases Ventripoint's AI-Powered Heart Imaging System
(TheNewswire)
Toronto, Ontario – TheNewswire – February 1 , 2024 - VentripointDiagnostics Ltd. (" Ventripoint " or the " Company "),(TSXV:VPT ) ; ( OTC:VPTDF), a leader in using AI forheart imaging, is pleased to announce ThePaediatric Heart Centre at the Medical University of Vienna has chosento adopt the VMS+ as its cardiac diagnostic tool.
The Paediatric Cardiology Department is part of theChildren’s Heart Centre Vienna and is the oldest pediatriccardiology department in Austria. The core unit is the Department ofPaediatric Cardiology, located at the University Hospital for Childrenand Adolescent Medicine.
“We are very excited to be partnering with thisworld-renowned hospital to bring our technology to the doctors andpatients at The Paediatric Heart Centre cardiac-care programs,” saidDr. Alvira Macanovic, Ventripoint’s CEO and President. “Thiscontinues our strategy of placing our VMS+ diagnostic units, whichoffer a cost-effective alternative to cardiac MRIs, in leadinghospitals around the world.”
Using the VMS+, caregivers at the Paediatric CardiologyDepartment can use ultrasound images to create detailed heart scans inminutes at a fraction of the costs of MRIs. The Paediatric CardiologyDepartment provides world-renowned care for children with heartdisease and is widely recognized for having industry leaders as itsmain care providers.
Ventripoint is committed to improving patient carethrough innovative technologies like the VMS+ and will continue tobring our AI-powered diagnostic technologies to healthcareprofessionals and institutions.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2024 TheNewswire - All rights reserved.